Skip to main content
CVE:ZOM

Zomedica Pharmaceuticals Corp. (ZOM.V) Competitors

C$0.28
-0.02 (-6.56 %)
(As of 02/5/2020)
Add
Compare
Today's Range
C$0.29
C$0.29
50-Day Range
C$0.29
C$0.29
52-Week Range
C$0.29
C$1.50
Volume4,800 shs
Average Volume2,858 shs
Market CapitalizationC$36.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Vs. EPI, WMD, NINE, ASP, FLWR, and RX

Should you be buying ZOM stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Zomedica Pharmaceuticals Corp. (ZOM.V), including ESSA Pharma (EPI), WeedMD (WMD), Delta 9 Cannabis (NINE), Acerus Pharmaceuticals (ASP), The Flowr (FLWR), and BioSyent (RX).

ESSA Pharma (CVE:EPI) and Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for ESSA Pharma and Zomedica Pharmaceuticals Corp. (ZOM.V), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma0000N/A
Zomedica Pharmaceuticals Corp. (ZOM.V)0000N/A

Profitability

This table compares ESSA Pharma and Zomedica Pharmaceuticals Corp. (ZOM.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/AN/AN/A
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A

Earnings & Valuation

This table compares ESSA Pharma and Zomedica Pharmaceuticals Corp. (ZOM.V)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/AN/AC($0.99)-8.27
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/AC($0.11)-2.61

ESSA Pharma is trading at a lower price-to-earnings ratio than Zomedica Pharmaceuticals Corp. (ZOM.V), indicating that it is currently the more affordable of the two stocks.

Summary

Zomedica Pharmaceuticals Corp. (ZOM.V) beats ESSA Pharma on 2 of the 2 factors compared between the two stocks.

WeedMD (CVE:WMD) and Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Earnings & Valuation

This table compares WeedMD and Zomedica Pharmaceuticals Corp. (ZOM.V)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WeedMDC$27.21 million2.58C$-21,702,912.00C($0.09)-3.24
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/AC($0.11)-2.61

Zomedica Pharmaceuticals Corp. (ZOM.V) has lower revenue, but higher earnings than WeedMD. WeedMD is trading at a lower price-to-earnings ratio than Zomedica Pharmaceuticals Corp. (ZOM.V), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares WeedMD and Zomedica Pharmaceuticals Corp. (ZOM.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WeedMDN/AN/AN/A
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for WeedMD and Zomedica Pharmaceuticals Corp. (ZOM.V), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
WeedMD02002.00
Zomedica Pharmaceuticals Corp. (ZOM.V)0000N/A

WeedMD currently has a consensus price target of C$0.58, indicating a potential upside of 104.68%. Given WeedMD's higher probable upside, analysts clearly believe WeedMD is more favorable than Zomedica Pharmaceuticals Corp. (ZOM.V).

Summary

WeedMD beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 3 of the 4 factors compared between the two stocks.

Delta 9 Cannabis (CVE:NINE) and Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares Delta 9 Cannabis and Zomedica Pharmaceuticals Corp. (ZOM.V)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$12.87 million6.94C$4.69 millionC$0.0519.07
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/AC($0.11)-2.61

Delta 9 Cannabis has higher revenue and earnings than Zomedica Pharmaceuticals Corp. (ZOM.V). Zomedica Pharmaceuticals Corp. (ZOM.V) is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Delta 9 Cannabis and Zomedica Pharmaceuticals Corp. (ZOM.V), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis0000N/A
Zomedica Pharmaceuticals Corp. (ZOM.V)0000N/A

Profitability

This table compares Delta 9 Cannabis and Zomedica Pharmaceuticals Corp. (ZOM.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A

Summary

Delta 9 Cannabis beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 3 of the 3 factors compared between the two stocks.

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Earnings & Valuation

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and Acerus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/AC($0.11)-2.61
Acerus PharmaceuticalsC$1.09 million70.86C$-55,353,168.00C($0.04)-1.39

Zomedica Pharmaceuticals Corp. (ZOM.V) has higher earnings, but lower revenue than Acerus Pharmaceuticals. Zomedica Pharmaceuticals Corp. (ZOM.V) is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Zomedica Pharmaceuticals Corp. (ZOM.V) and Acerus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zomedica Pharmaceuticals Corp. (ZOM.V)0000N/A
Acerus Pharmaceuticals0000N/A

Profitability

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A
Acerus PharmaceuticalsN/AN/AN/A

Summary

Acerus Pharmaceuticals beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 3 of the 3 factors compared between the two stocks.

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) and The Flowr (CVE:FLWR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and The Flowr's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/AC($0.11)-2.61
The FlowrC$7.51 million11.56C$-343,678,650.00C($0.95)-0.25

Zomedica Pharmaceuticals Corp. (ZOM.V) has higher earnings, but lower revenue than The Flowr. Zomedica Pharmaceuticals Corp. (ZOM.V) is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and The Flowr, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zomedica Pharmaceuticals Corp. (ZOM.V)0000N/A
The Flowr0000N/A

The Flowr has a consensus target price of C$0.88, indicating a potential upside of 268.06%. Given The Flowr's higher probable upside, analysts clearly believe The Flowr is more favorable than Zomedica Pharmaceuticals Corp. (ZOM.V).

Profitability

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and The Flowr's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A
The FlowrN/AN/AN/A

Summary

The Flowr beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 3 of the 4 factors compared between the two stocks.

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and BioSyent, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zomedica Pharmaceuticals Corp. (ZOM.V)0000N/A
BioSyent02002.00

BioSyent has a consensus target price of C$7.00, indicating a potential downside of 7.89%. Given BioSyent's higher probable upside, analysts clearly believe BioSyent is more favorable than Zomedica Pharmaceuticals Corp. (ZOM.V).

Profitability

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A
BioSyentN/AN/AN/A

Earnings and Valuation

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and BioSyent's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/AC($0.11)-2.61
BioSyentC$22.33 million4.32C$3.68 millionC$0.2926.21

BioSyent has higher revenue and earnings than Zomedica Pharmaceuticals Corp. (ZOM.V). Zomedica Pharmaceuticals Corp. (ZOM.V) is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Summary

BioSyent beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 4 of the 4 factors compared between the two stocks.


Zomedica Pharmaceuticals Corp. (ZOM.V) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
EPI
ESSA Pharma
0.6$8.20-6.7%C$145.78 millionN/A-8.27
WMD
WeedMD
1.3$0.29-1.8%C$95.35 millionC$27.21 million-3.24
NINE
Delta 9 Cannabis
1.1$1.03-2.9%C$89.36 millionC$12.87 million19.07Gap Up
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05-0.0%C$76.88 millionC$1.09 million-1.39News Coverage
FLWR
The Flowr
1.0$0.24-2.1%C$70.01 millionC$7.51 million-0.25
RX
BioSyent
0.8$7.60-0.5%C$64.81 millionC$22.33 million26.21
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.60-18.8%C$43.16 millionC$21.61 million7.96News Coverage
MDP
Medexus Pharmaceuticals
0.6$7.00-0.0%C$38.66 millionC$108.29 million-3.87Gap Up
VIR
Viridium Pacific Group
0.7$0.38-5.3%C$37.54 millionC$1.09 million-2.97Gap Up
IN
InMed Pharmaceuticals
0.6$4.19-1.7%C$33.73 millionN/A-2.40
NDVA
Indiva
1.3$0.44-2.3%C$27.54 millionC$7.92 million-3.44Gap Up
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.09-5.9%C$21.51 millionC$8.50 million-0.24News Coverage
EVE
Eve & Co Incorporated
1.0$0.26-2.0%C$21.32 millionC$2.84 million-0.80
SUGR
SugarBud Craft Growers
0.7$0.05-0.0%C$11.81 millionC$66,906.00-0.03
NU
NeutriSci International
0.5$0.16-0.0%C$8.65 millionC$74,572.00-11.07
AQS
Aequus Pharmaceuticals
0.9$0.15-6.7%C$6.03 millionC$2.59 million-13.64Gap Down
LBL
Lattice Biologics
0.5$0.04-12.5%C$4.67 millionC$2.24 million-2.22Gap Down
THCX
(THCX.V)
0.6$5.30-6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Up
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Up
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Up
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Up
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.